Are Valeant Pharmaceuticals Intl Inc. and Concordia Healthcare Corp. Bargains After Crashing?

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) and Concordia Healthcare Corp. (TSX:CXR)(NYSE:CXRX) have seen their share prices absolutely plunge.

The Motley Fool

The past week and a half has not been fun for shareholders of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) or Concordia Healthcare Corp. (TSX:CXR)(NYSE:CXRX). At the beginning of last week, the two companies’ stocks traded at $97 and $319, respectively. By the close of trading Tuesday, those prices had fallen to $48 and $212.

So, what exactly caused these crashes, and are these two stocks now a bargain?

Fed up over high drug prices

Prescription drug prices have become a hot topic recently in the United States, thanks largely to the actions of biotech entrepreneur Martin Shkreli. Back in August, Mr. Skreli’s company acquired the rights to Daraprim, a drug that treats a rare parasitic infection, and instantly raised its price by a factor of 55.

And it’s clear where Americans stand on the issue. According to the Kaiser Health Tracking Poll, over 70% of Americans think the cost of drugs is unreasonably high. And 76% of Americans think that “Making sure that high-cost drugs for chronic conditions are affordable to those who need them” should be a top priority for the president and Congress.

No other healthcare-related goal got that much support. Even among Republicans, controlling drug costs is a higher priority than repealing Obamacare.

How Valeant and Condordia are affected

Mr. Shkreli is not the only one facing scrutiny. Valeant has also come under fire for its tactics, especially with regards to two heart drugs. Democrats in Congress have even demanded that Valeant be subpoenaed, which caused Valeant’s share price to crash more than 16% on Monday.

Concordia is also vulnerable, because it had just filed a public offering to raise US$520 million, which will be used to finance a US$3.5 billion acquisition.

Where do we go from here?

Democratic frontrunner Hillary Clinton has already responded to the controversy, proposing some fairly drastic measures to cut drug prices. This includes capping patients’ drug costs at US$250 per month, and a minimum level of R&D expenses for most drug makers.

There are other things that can be done. A huge majority of Americans are in favour of importing more cheap drugs from Canada. There is also broad support for Medicare negotiating drug prices.

Either of these initiatives would hurt Concordia and Valeant. The U.S. accounts for practically all of Concordia’s revenue, and over 60% of Valeant’s. Making matters worse, both companies are heavily indebted, so any change in business prospects could have a big impact on equity value. And to top it all off, both companies’ share prices are very expensive by most standards.

Granted, we are still talking about U.S. politics, so there’s a good chance that nothing will change. And in that case, there’s plenty of upside for these stocks, especially Concordia’s. But this is a very dangerous game to play, one that you should probably stay away from.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

oil pumps at sunset
Energy Stocks

How a $25,000 TFSA Could Fund Your Retirement

Canadians can turn to the TFSA to help provide a meaningful income stream in retirement.

Read more »

Canada day banner background design of flag
Investing

3 of the Best Canadian Stocks to Buy Right Now

These three Canadian stocks are ideal for balancing wealth-creation opportunities with stability and income generation in this uncertain outlook.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Strategy: How to Earn $500 a Month in Tax-Free Dividend Income

Canadians can earn $500 in tax-free dividend income or another desired amount every month using a simple TFSA strategy.

Read more »

coins jump into piggy bank
Energy Stocks

Canadian Natural Resources vs. Enbridge: The Better Dividend Stock to Buy Today

Both CNQ and ENB have impressive payout records, consistently paying and increasing their dividends for decades.

Read more »

doctor uses telehealth
Dividend Stocks

TFSA Investors: This Monthly Dividend Stock Yields 7.6%

This REIT offers investors a monthly yield investors and a regular and frequent passive income stream to supplement their regular…

Read more »

shopper chooses vegetables at grocery store
Dividend Stocks

Loblaw vs. Empire: Which Grocery Stock Would I Choose for Long-Term Growth?

Both grocers benefit from repeat shoppers. I’d give Loblaw the edge for the ways it can earn more from those…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Canadian Stocks to Buy and Hold for 20 More Years

CP Rail (TSX:CP) and another outstanding Canadian stock that's more than worth holding for many decades.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

2 Top TSX ETFs to Buy and Hold in a TFSA Forever

Looking for top TSX ETFs for your TFSA? Explore how VFV and VDY combine U.S. stock exposure and Canadian dividends…

Read more »